Common COVID-19 antibiotic no more effective than placebo
Research News Release
EurekAlert! provides eligible reporters with free access to embargoed and breaking news releases.
Eligibility GuidelinesEurekAlert! offers eligible public information officers paid access to a reliable news release distribution service.
Eligibility GuidelinesEurekAlert! is a service of the American Association for the Advancement of Science.
A UC San Francisco study has found that the antibiotic azithromycin was no more effective than a placebo in preventing symptoms of COVID-19 among non-hospitalized patients, and may increase their chance of hospitalization, despite widespread prescription of the antibiotic for the disease.
Messenger RNA vaccines against COVID-19 were not detected in human milk, according to a small study by UC San Francisco, providing early evidence that the vaccine mRNA is not transferred to the infant.
A new study by Vanderbilt University Medical Center researchers of more the 400,000 Medicare patients taking medications for insomnia found that the risk of death is increased when either benzodiazepines or "z-drugs" are taken with opioids.
Silicon is a microelement that in low doses is vital for the normal development and functioning of connective tissue. Experiments showed that after only a few months of consuming water with added silicon animals developed a condition similar to silicosis (or miners lung disease).
To date, there are no effective antidotes against most virus infections. An interdisciplinary research team at the Technical University of Munich (TUM) has now developed a new approach: they engulf and neutralize viruses with nano-capsules tailored from genetic material using the DNA origami method. The strategy has already been tested against hepatitis and adeno-associated viruses in cell cultures. It may also prove successful against corona viruses.
The mitochondrion has garnered quite the reputation for its role as the "powerhouse of the cell." These tiny, but mighty organelles play various life-sustaining roles, from powering our own cells and organs to fueling chemical and biological processes. But when they aren't working properly, a number of rare diseases can occur.
Protein design researchers have created a freely available method, RoseTTAFold, to provide access to highly accurate protein structure prediction. Scientists around the world are using it to build protein models to accelerate their research. The tool uses deep learning to quickly predict protein structures based on limited information, thereby compressing the time for what would have taken years of lab work on just one protein. Predicting intricate shapes of proteins vital to specific biological processes could speed treatment development for many diseases.
A preclinical study offers hope for treatment of uveal melanoma, a rare and deadly cancer of the eye. A small molecule inhibitor has been identified that dampens the potent drivers of this tumor. In mouse models, the inhibitor strongly limited primary disease in the eye and metastatic tumor dissemination to the liver, and animals survived longer, without overt side effects.
A team of University of Houston pharmaceutical researchers is reporting a newly recognized process of drug metabolism in the intestines - followed by recycling through the liver - that could have important implications for developing treatments for intestinal diseases and for taking multiple medications at the same time.
More doesn't necessarily mean better - including in cancer treatment. University of Pittsburgh School of Medicine and University of Wisconsin-Madison scientists report today in Science Translational Medicine that combining targeted radiopharmaceutical therapy with immunotherapy significantly boosts eradication of metastatic cancer in mice, even when the radiation is given in doses too low to destroy the cancer outright.